AleÅ¡ Å orf

List of Publications by Year
in descending order

10 papers	144 citations	1307594 7 h-index	1372567 10 g-index
10 all docs	10 docs citations	10 times ranked	215 citing authors

#	ARTICLE	IF	CITATIONS
1	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology, 2018, 154, 10-17.	4.4	41
2	Brivanib Exhibits Potential for Pharmacokinetic Drugâ€“Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Molecular Pharmaceutics, 2019, 16, 4436-4450.	4.6	22
3	In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?. Medicinal Chemistry, 2018, 14, 281-292.	1.5	19
4	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition, 2019, 47, 699-709.	3.3	15
5	Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. Drug Metabolism and Disposition, 2019, 47, 954-960.	3.3	13
6	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers, 2020, 12, 1596.	3.7	13
7	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology, 2019, 163, 290-298.	4.4	9
8	S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein. Pharmaceutical Research, 2020, 37, 58.	3.5	4
9	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicology and Applied Pharmacology, 2022, 434, 115797.	2.8	4
10	ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. Biomedicine and Pharmacotherapy, 2022, 150, 112962.	5.6	4